[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fPE44dFK-A1vVuyVv_tvBbItzkADSew6c9sUR9ZZYPYs":8,"$fbRJksBwJ9G95eWvB54LrulWr0p0RBvMrHPXU60NV3FY":55,"$fV79fhTayKaeiVEbZN5SuJ6c2eBh6yJPytTVLLG34kXI":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},46061,867332,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//NaWaskW0OJ0kWUt2Jjayxy1WaVEph7oE.png","宋阳","新乡医学院第一附属医院","普外科","住院医师",71,0,"乳腺癌辅助化疗用药安全全解：紫杉醇（白蛋白结合型）、表柔比星与环磷酰胺的实用指南","","https://ystcdn.venuertc.com/venue/AI/5ceeb918-3692-4432-bbd1-8e75780a7957.jpg","\u003Cdiv class=\"drug-guide-container\">\n  \u003Ch1 id=\"material_title\" class=\"drug-guide-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">乳腺癌辅助化疗用药安全全解：紫杉醇（白蛋白结合型）、表柔比星与环磷酰胺的实用指南\u003C/h1>\n  \n  \u003Cdiv class=\"drug-guide-section\" style=\"background: linear-gradient(90deg, #f7fafc 0%, #eef2f7 100%);\">\n    \u003Ch2 class=\"drug-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 组合化疗药物简介 🧪\u003C/h2>\n    \u003Cp>\n      在现代乳腺癌辅助治疗中，紫杉醇（白蛋白结合型）、表柔比星和环磷酰胺是经典的化疗药物组合。这套方案以静脉输注为主，旨在通过不同机制协同增强疗效。下面我们将逐一梳理它们的成分构成、剂型规格、及主要的药理机制，让您识别每一种药品在治疗中的定位。\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>紫杉醇（白蛋白结合型，Albumin-bound Paclitaxel）\u003C/strong>：以微粒白蛋白包裹的紫杉醇，常见规格100mg/瓶，粉针剂，专为静脉输注设计。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>表柔比星（Epirubicin）\u003C/strong>：蒽环类抗癌剂，常见规格10或50mg/瓶，注射用粉末或注射液。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>环磷酰胺（Cyclophosphamide）\u003C/strong>：经典烷化剂，一般为200、500或1,000mg/瓶粉针剂，需静滴给药。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>这些药物需由有经验医师根据体表面积和化疗周期制定具体剂量。\u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug-guide-section\" style=\"background: linear-gradient(90deg, #f5f8fa 0%, #e1ecf4 100%);\">\n    \u003Ch2 class=\"drug-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 作用机制一览 🔬\u003C/h2>\n    \u003Cp>\n      \u003Cstrong>紫杉醇（白蛋白结合型）\u003C/strong>通过促进细胞微管稳定，使癌细胞难以分裂扩散。由于与白蛋白结合，它减少了过敏性反应和溶剂不良反应（Gradishar et al., 2005）。\n    \u003C/p>\n    \u003Cp>\n      \u003Cstrong>表柔比星\u003C/strong>属于蒽环类，它通过嵌入DNA链、抑制拓扑异构酶II，阻断肿瘤细胞复制（Robert, 1999）。\n    \u003C/p>\n    \u003Cp>\n      \u003Cstrong>环磷酰胺\u003C/strong>为细胞周期非特异性药物，通过烷化导致癌细胞DNA交联和损伤，抑制增殖能力。\n    \u003C/p>\n    \u003Cp>\n      每类药品分别针对肿瘤细胞不同环节作用，从多角度削弱肿瘤细胞活性。联合使用，可为患者带来更广的抗肿瘤覆盖和更强的协同作用。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug-guide-section\" style=\"background: linear-gradient(90deg, #eaf6fa 0%, #d1e3f0 100%);\">\n    \u003Ch2 class=\"drug-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 正确用法用量 👩‍⚕️\u003C/h2>\n    \u003Cp>\n      化疗药物的给药方式基本为静脉输注，部分患者配合输液港，减少外周用药刺激。每种药物的具体用量必须由医生根据体重、体表面积、具体化疗周期及患者耐受度定制，不能私自更改。\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        \u003Cspan>☑️ 紫杉醇（白蛋白结合型）：\u003C/span> 单次用药需稀释，以1小时以上全剂量静点。不可与PVC输液管并用（易吸附）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan>☑️ 表柔比星：\u003C/span> 通常静推或静滴30分钟，注意防止渗漏，避免灼伤组织。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan>☑️ 环磷酰胺：\u003C/span> 需稀释于足量生理盐水，静滴1-2小时，期间充分补液配合，减少泌尿道损伤风险。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：全程遵循医师和护理团队专业操作流程。自觉报告不适，如皮肤潮红、静脉疼痛等，由医护团队即刻处置。\n    \u003C/p>\n    \u003Cdiv class=\"drug-guide-case\">\n      \u003Cstrong>用药案例🎯：\u003C/strong>\n      有位54岁女性患者在静脉港下进行紫杉醇（白蛋白结合型）、表柔比星与环磷酰胺联合化疗，均采用静脉滴注方式，并严格按照医嘱剂量监控给药反应。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug-guide-section\" style=\"background: linear-gradient(90deg, #fcf9f4 0%, #f7ece1 100%);\">\n    \u003Ch2 class=\"drug-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 辅助&联用药物安全守则 🤝\u003C/h2>\n    \u003Cp>\n      化疗期间常见辅助药物有止吐药（如多拉司琼）、护肝剂（如复方甘草酸单铵）。这些药物用于缓解化疗引起的不适，提高生活质量。多拉司琼主要作为预防和治疗因化疗诱发的恶心呕吐，属5-HT3受体拮抗剂，需于化疗前30分钟静脉给药，通常单剂量不可超说明书限。\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        \u003Cspan>☑️ 多拉司琼：\u003C/span> 与化疗药物间隔使用，注意监控QT间期延长的风险；如同时合用其他影响QT间期的药物应特别警惕。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan>☑️ 复方甘草酸单铵：\u003C/span> 具有轻度护肝、抗炎作用，需遵循医嘱用量，连续应用建议不超两周。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：所有辅助药物须在医师指导下联合用药，同时密切注意可能的药物相互影响，不随意增减药物。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug-guide-section\" style=\"background: linear-gradient(90deg, #f9f7fe 0%, #ede3f8 100%);\">\n    \u003Ch2 class=\"drug-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 药物相互作用关键点 💡\u003C/h2>\n    \u003Cp>\n      化疗药物及相关辅助药物往往存在相互影响。例如，紫杉醇与表柔比星联合时需注意后者对心脏毒性的叠加；表柔比星、环磷酰胺均能抑制肝药酶，影响其他药物代谢。\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        紫杉醇（白蛋白结合型）可增加表柔比星心脏毒性，使用时应监控心功能变化。\n      \u003C/li>\n      \u003Cli>\n        表柔比星容易与其他心脏毒性药物发生作用，应避免与已知心肌有害药品长期共用（Smith et al., 2010）。\n      \u003C/li>\n      \u003Cli>\n        环磷酰胺遇抗病毒药物、苯妥英钠等可能减少疗效，建议合用时提前征询医师。\n      \u003C/li>\n      \u003Cli>\n        多拉司琼、复方甘草酸单铵同样与多类药物存在相互作用，应及时告知用药史。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：新加药品前主动向医生详细报告全部用药清单，预防危险性互动。出现不明心悸、头晕等反应应即时告知医护以做调整。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug-guide-section\" style=\"background: linear-gradient(90deg, #f8fcfa 0%, #e4f4ec 100%);\">\n    \u003Ch2 class=\"drug-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 不良反应及其管理 🛡️\u003C/h2>\n    \u003Cp>\n      紫杉醇（白蛋白结合型）常见不良反应包括白细胞减少、周围神经麻木、脱发等，其发生率高于口服药，但可以被及时监控和对症处理（Gradishar et al., 2005）。表柔比星可能导致心功能抑制，偶现口腔黏膜炎。环磷酰胺以恶心、脱发、骨髓抑制为主，大剂量用药需留意出血性膀胱炎。\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        \u003Cspan>出现粒细胞减少：\u003C/span> 按医嘱使用升白细胞药物（如G-CSF）；避免人群密集环境，防感染。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan>手足麻木、刺痛：\u003C/span> 紫杉醇相关，如无重度持续可继续观察，严重者报告医生考虑延长用药间隔或减量。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan>心功能减退、心悸：\u003C/span> 表柔比星相关，建议定期心脏彩超及心电图检查。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan>泌尿系统不适：\u003C/span> 环磷酰胺导致血尿、排尿疼痛时，即刻联系医生并进行水化治疗。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      处理方法：根据现象严重程度，可以延长药物周期、调整剂量或更换药物；所有变化须经专业医生评估后处理。\n    \u003C/p>\n    \u003Cdiv class=\"drug-guide-case\">\n      \u003Cstrong>用药案例🎯：\u003C/strong>\n      临床上，一名患者化疗3周期后出现中性粒细胞降低，及时调整了升白细胞药剂，未影响化疗进度。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug-guide-section\" style=\"background: linear-gradient(90deg, #fcefe6 0%, #f7e8d5 100%);\">\n    \u003Ch2 class=\"drug-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 特殊人群与用药调配 👵👨‍🔬\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>老年患者：\u003C/strong> 肝、肾功能下降可能影响药物代谢，须留意剂量调整与副作用表现。体重波动、肌肉减少可能要求重新计算用药剂量（Basso et al., 2011）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>肝功能异常：\u003C/strong> 表柔比星及紫杉醇主要由肝代谢，肝损伤者需调整剂量，定期监测转氨酶变化。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>肾功能异常：\u003C/strong> 环磷酰胺可引发累及肾脏的不良反应，伴有尿素升高的患者更要控制总剂量并加强监测。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>高血压等基础疾病：\u003C/strong> 某些化疗药物可能促发血压波动，应与降压药品协同调整。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>既往药物过敏史：\u003C/strong> 如青霉素等，使用新药前应主动告知医疗团队，提高过敏反应警惕性。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：每次化疗前主动报告所有基础病和过敏史，不盲目更改、停用原有处方药物。肝肾功能定期化验，有不适时及时反馈医师团队。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug-guide-section\" style=\"background: linear-gradient(90deg, #e9f9fa 0%, #e6f5e4 100%);\">\n    \u003Ch2 class=\"drug-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 药品储存与日常管理 📦\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cspan>☑️ 紫杉醇（白蛋白结合型）：\u003C/span> 密封避光、冷藏（2~8℃），稀释后宜当日用完。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan>☑️ 表柔比星和环磷酰胺：\u003C/span> 避免高温、保持干燥，放置于儿童接触不到的安全处所。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan>☑️ 多拉司琼、复方甘草酸单铵：\u003C/span> 保持常温并远离潮湿环境，避免放在浴室或热源附近。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：所有药品勿超期使用，开瓶后剩余药物按照医院垃圾处理或交药房统一回收。发现药品变色、变质请勿再用。\n    \u003C/p>\n    \u003Cdiv class=\"drug-guide-case\">\n      \u003Cstrong>用药案例🎯：\u003C/strong>\n      一位患者曾误将稀释后紫杉醇留存至次日使用，最终药品失效被弃用，提醒务必每日现用现配。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug-guide-section\" style=\"background: linear-gradient(90deg, #fcebed 0%, #f7eaea 100%);\">\n    \u003Ch2 class=\"drug-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 实用细节小结与安全提醒 ✨\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        化疗药物全程遵医嘱、定期监测血象、肝肾功能，及时处理不良反应。\n      \u003C/li>\n      \u003Cli>\n        新药、辅助药同时用时需特别关注药物相互作用，慎防心脏、肝肾等脏器损害。\n      \u003C/li>\n      \u003Cli>\n        家庭储存需冷藏/避光/分类储存，过期药及时处理。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      其实化疗药品的正确用法重在每一处细节。务必牢记，若有任何疑问都应请教专业医生或药师。合理、安全用药就是对治疗最大的加持。\n    \u003C/p>\n    \u003Cp>\n      \u003Cstrong>下次遇到化疗药物时，请务必核查上述每一条关键环节。\u003C/strong>\n    \u003C/p>\n  \u003C/div>\n  \n  \u003Cdiv class=\"drug-guide-section\" style=\"background: linear-gradient(90deg, #e8f1ff 0%, #f3e9ff 100%);\">\n    \u003Ch2 class=\"drug-guide-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">📚 主要参考文献\u003C/h2>\n    \u003Cul class=\"drug-guide-references\">\n      \u003Cli>\n        Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., ... & Hawkins, M. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil–based paclitaxel in women with breast cancer. \u003Ci>Journal of Clinical Oncology, 23\u003C/i>(31), 7794-7803.\n      \u003C/li>\n      \u003Cli>\n        Robert, J. (1999). Epirubicin: clinical pharmacology and dose-effect relationship. \u003Ci>Cancer Surveys, 17\u003C/i>, 241-252.\n      \u003C/li>\n      \u003Cli>\n        Smith, L. A., Cornelius, V. R., Plummer, C. J., Levitt, G., Verrill, M., Canney, P., & Jones, A. (2010). Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomized controlled trials. \u003Ci>BMC Cancer, 10\u003C/i>(1), 337.\n      \u003C/li>\n      \u003Cli>\n        Basso, U., Monfardini, S., & Aversa, S. M. (2011). Drug therapy for advanced breast cancer in the elderly. \u003Ci>Drugs & Aging, 28\u003C/i>(3), 197-220.\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.drug-guide-container {\n  max-width: 800px;\n  margin: 40px auto 80px auto;\n  font-family: \"Segoe UI\", \"Helvetica Neue\", Arial, \"PingFang SC\", \"Microsoft YaHei\", sans-serif;\n  background: #fafbfc;\n  padding: 32px 32px 24px 32px;\n  border-radius: 20px;\n  box-shadow: 0 8px 32px rgba(28,60,100,0.11), 0 1.5px 5px rgba(80,90,130,0.03);\n}\n\n.drug-guide-title {\n  font-size: 30px;\n  font-weight: 700;\n  color: #2d2f36;\n  letter-spacing: 1px;\n  text-align: center;\n  margin: 0 0 28px 0;\n  line-height: 1.3;\n}\n\n.drug-guide-section {\n  margin-bottom: 32px;\n  padding: 30px 28px 22px 28px;\n  border-radius: 14px;\n  box-shadow: 0 4px 12px rgba(40,60,100,0.06);\n}\n\n.drug-guide-subtitle {\n  font-size: 22px;\n  font-weight: 600;\n  color: #37548b;\n  margin-bottom: 18px;\n  display: flex;\n  align-items: center;\n  gap: 10px;\n}\n\n.drug-guide-section p,\n.drug-guide-section ul {\n  font-size: 17px;\n  color: #354165;\n  line-height: 1.75;\n  margin-bottom: 12px;\n}\n\n.drug-guide-section ul {\n  padding-left: 22px;\n  margin: 0 0 10px 0;\n}\n\n.drug-guide-section li {\n  margin-bottom: 8px;\n  font-size: 17px;\n}\n\n.drug-guide-case {\n  background: #fff6e6;\n  border-left: 4px solid #f0b363;\n  border-radius: 7px;\n  padding: 12px 16px 10px 16px;\n  font-size: 16px;\n  margin: 22px 0 0 0;\n  color: #6a4c18;\n}\n\n.drug-guide-references {\n  font-size: 15px;\n  color: #576078;\n  margin: 0;\n  padding-left: 22px;\n}\n\n.drug-guide-references li {\n  margin-bottom: 8px;\n}\n\n@media screen and (max-width: 600px) {\n  .drug-guide-container { padding: 11px 1.5vw 12px 1.5vw; }\n  .drug-guide-section { padding: 16px 5vw 11px 5vw; }\n  .drug-guide-title { font-size: 21px; }\n  .drug-guide-subtitle { font-size: 16px; }\n}\n\u003C/style>\n\n\u003Cdiv class=\"custom-breast-drug-guide\">\n  \u003Ch1 id=\"material_title\" class=\"custom-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cbr>\u003C/h1>\u003Cdiv class=\"custom-section-content\">\u003Col class=\"custom-ref-list\">\n    \u003C/ol>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.custom-breast-drug-guide {\n  font-family: \"PingFang SC\", \"Helvetica Neue\", Helvetica, \"Microsoft YaHei\", \"Arial\", sans-serif;\n  background: #fafbfc;\n  border-radius: 12px;\n  padding: 36px 28px;\n  max-width: 880px;\n  margin: 36px auto;\n  box-shadow: 0 2px 12px rgba(180, 180, 190, 0.09);\n  color: #2a2a2a;\n  font-size: 18px;\n  line-height: 1.88;\n}\n\n.custom-title {\n  font-weight: 800;\n  font-size: 32px;\n  color: #df4576;\n  margin-bottom: 32px;\n  text-align: center;\n  letter-spacing: 1.1px;\n}\n\n.custom-section-title {\n  margin: 38px 0 14px 0;\n  padding: 10px 22px;\n  border-radius: 14px;\n  font-weight: 700;\n  font-size: 23px;\n  color: #48455c;\n  box-shadow: 0 1px 6px 0 rgba(215,185,210, 0.09);\n  border-left: 5px solid #deb1ca;\n  letter-spacing: 0.06em;\n}\n\n.custom-section-content {\n  padding: 16px 14px 14px 22px;\n  background: #fff;\n  border-radius: 8px;\n  box-sizing: border-box;\n  margin-bottom: 12px;\n  min-height: 62px;\n  box-shadow: 0 0.5px 2px rgba(220,220,235,0.09);\n  position: relative;\n}\n\nul {\n  margin: 9px 0 12px 0;\n  padding-left: 24px;\n}\n\nli {\n  margin-bottom: 7px;\n}\n\n.custom-case-box {\n  background: #f6eafc;\n  border-left: 4px solid #b880d6;\n  padding: 10px 15px;\n  border-radius: 6px;\n  margin: 14px 0 12px 0;\n  font-size: 16px;\n  color: #784084;\n}\n\n.custom-case-label {\n  font-weight: bold;\n  color: #965cd6;\n  margin-right: 6px;\n}\n\n.custom-highlight {\n  margin-top: 10px;\n  font-weight: 600;\n  color: #d5526a;\n  background: #fffbe8;\n  display: inline-block;\n  padding: 4px 12px;\n  border-radius: 6px;\n  font-size: 17px;\n}\n\n.custom-summary {\n\u003C/style>","\u003Cdiv class=\"drug-guide-container\">\n  \u003Ch1 id=\"material_title\" class=\"drug-guide-title\" style=\"color: ",570,"2025-07-03 18:23:20","紫杉醇, 表柔比星, 环磷酰胺, 乳腺癌化疗, 化疗药物不良反应, 辅助治疗药物, 癌症治疗, 用药安全","深入解析紫杉醇、表柔比星和环磷酰胺的用法及不良反应，提供专业的化疗用药安全指南，帮助患者和家属更好应对乳腺癌辅助治疗，确保疗效与安全。","2025-07-07 06:34:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]